Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Genomic and immune signatures associated with resistance in patients with myeloma treated with D-KRd

Although treatment regimens consisting of anti-CD38 monoclonal antibodies, proteasome inhibitors and immunomodulatory drugs (IMiDs) have significantly improved the outcomes of patients with multiple myeloma, with measurable residual disease (MRD)-negativity rates of over 70%, many still experience disease progression. Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, gives an overview of the findings of a study using whole-genome sequencing (WGS) and single-cell RNA-sequencing (scRNA-seq) to define the genomic and immune microenvironment signatures associated with resistance in patients with multiple myeloma treated with daratumumab, carfilzomib, lenalidomide and dexamethasone (D-KRd). It was shown that resistance is due to a complex interplay between tumor cells and the immune microenvironment. In addition, the study identified distinct genomic lesions associated with distinct microenvironment signatures, and distinct cell populations playing a role in response to therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.